[go: up one dir, main page]

WO2003076578A3 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use - Google Patents

Therapeutic polypeptides, nucleic acids encoding same, and methods of use Download PDF

Info

Publication number
WO2003076578A3
WO2003076578A3 PCT/US2003/006794 US0306794W WO03076578A3 WO 2003076578 A3 WO2003076578 A3 WO 2003076578A3 US 0306794 W US0306794 W US 0306794W WO 03076578 A3 WO03076578 A3 WO 03076578A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nucleic acids
acids encoding
encoding same
therapeutic polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/006794
Other languages
French (fr)
Other versions
WO2003076578A2 (en
Inventor
John P Ii Alsobrook
David W Anderson
Ferenc L Boldog
Catherine E Burgess
Amitabha Chaudhuri
Steven D Colman
Shlomit R Edinger
Seth Ettenberg
Esha A Gangolli
Valerie L Gerlach
Linda Gorman
Xiaojia Guo
Ramesh Kekuda
Li Li
Timothy Maclachlan
Uriel M Malyankar
Peter S Mezes
Charles E Miller
Isabelle Millet
Muralidhara Padigaru
Meera Patturajan
John Peyman
Xiazhong Qian
Luca Rastelli
Daniel K Rieger
Glennda Smithson
Kimberly A Spytek
David J Stone
Sujatha Sukumaran
Corine A M Vernet
Edward Z Voss
Mei Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/093,463 external-priority patent/US20030208039A1/en
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to AU2003228284A priority Critical patent/AU2003228284A1/en
Priority to EP03726032A priority patent/EP1572922A2/en
Priority to CA002478032A priority patent/CA2478032A1/en
Priority to JP2003574785A priority patent/JP2006501813A/en
Publication of WO2003076578A2 publication Critical patent/WO2003076578A2/en
Anticipated expiration legal-status Critical
Publication of WO2003076578A3 publication Critical patent/WO2003076578A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to novel polypeptides, and the nucleic acids encoding them, having properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions.
PCT/US2003/006794 2002-03-06 2003-03-06 Therapeutic polypeptides, nucleic acids encoding same, and methods of use Ceased WO2003076578A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003228284A AU2003228284A1 (en) 2002-03-06 2003-03-06 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP03726032A EP1572922A2 (en) 2002-03-06 2003-03-06 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA002478032A CA2478032A1 (en) 2002-03-06 2003-03-06 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2003574785A JP2006501813A (en) 2002-03-06 2003-03-06 Therapeutic polypeptides, nucleic acids encoding the same, and methods of use

Applications Claiming Priority (38)

Application Number Priority Date Filing Date Title
US36197402P 2002-03-06 2002-03-06
US60/361,974 2002-03-06
US10/093,463 US20030208039A1 (en) 2001-03-08 2002-03-08 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
US10/093,463 2002-03-08
PCT/US2002/007288 WO2002072771A2 (en) 2001-03-08 2002-03-08 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
USPCT/US02/07288 2002-03-08
US36503402P 2002-03-15 2002-03-15
US60/365,034 2002-03-15
US36547702P 2002-03-19 2002-03-19
US60/365,477 2002-03-19
US36598502P 2002-03-20 2002-03-20
US36588402P 2002-03-20 2002-03-20
US36598402P 2002-03-20 2002-03-20
US60/365,984 2002-03-20
US60/365,985 2002-03-20
US60/365,884 2002-03-20
US36692802P 2002-03-22 2002-03-22
US60/366,928 2002-03-22
US37202202P 2002-04-12 2002-04-12
US37201802P 2002-04-12 2002-04-12
US60/372,022 2002-04-12
US60/372,018 2002-04-12
US37468202P 2002-04-23 2002-04-23
US60/374,682 2002-04-23
US38809602P 2002-06-12 2002-06-12
US60/388,096 2002-06-12
US38914302P 2002-06-14 2002-06-14
US60/389,143 2002-06-14
US39177902P 2002-06-26 2002-06-26
US60/391,779 2002-06-26
US40374302P 2002-08-15 2002-08-15
US60/403,743 2002-08-15
US41075502P 2002-09-13 2002-09-13
US60/410,755 2002-09-13
US41295702P 2002-09-23 2002-09-23
US60/412,957 2002-09-23
US42038202P 2002-10-22 2002-10-22
US60/420,382 2002-10-22

Publications (2)

Publication Number Publication Date
WO2003076578A2 WO2003076578A2 (en) 2003-09-18
WO2003076578A3 true WO2003076578A3 (en) 2006-09-28

Family

ID=27809011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006794 Ceased WO2003076578A2 (en) 2002-03-06 2003-03-06 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Country Status (3)

Country Link
EP (1) EP1572922A2 (en)
JP (1) JP2006501813A (en)
WO (1) WO2003076578A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632218B1 (en) * 2004-05-22 2007-05-09 KPSS-Kao Professional Salon Services GmbH Composition for dyeing keratin fibres
ATE361774T1 (en) * 2004-05-22 2007-06-15 Kpss Kao Gmbh COMPOSITION FOR DYING KERATIN FIBERS
WO2006055704A2 (en) * 2004-11-17 2006-05-26 Curagen Corporation Antibodies directed to ten-m proteins and uses thereof
JPWO2006062135A1 (en) * 2004-12-07 2008-06-12 独立行政法人理化学研究所 Diagnostic agents for mental disorders
WO2006116681A2 (en) * 2005-04-28 2006-11-02 Caprion Pharmaceuticals, Inc. Tat-003 and methods of assessing and treating cancer
ES2429794T3 (en) * 2007-08-15 2013-11-15 Metamorefix Peptides and pharmaceutical compositions for treating connective tissue
US20110275573A1 (en) * 2008-11-03 2011-11-10 Metamorefix Ltd. Tissue adhesive
EP2403870A1 (en) * 2009-03-03 2012-01-11 Metamorefix Ltd. Peptides derived from ficolin as surfactants

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENEMBL [online] KASAHARA M. ET AL.: "CLoning and mapping of a testis-specific gene with sequence similarity to a sperm-coating glycoprotein gene", XP003002331, Database accession no. (M25532) *
DATABASE UNIPROT [online] KASAHARA M. ET AL.: "Cloning and mapping of a testis-specific gene with sequence similarity to a sperm-coating glycoprotein gene", XP003001984, Database accession no. (P16562) *
GENOMICS, vol. 5, no. 3, 1989, pages 527 - 534 *
KASAHARA ET AL.: "Cloning and mapping of a testis-specific gene with sequence similarity to a sperm-coating glycoprotein gene", GENOMICS, vol. 5, no. 3, 1989, pages 527 - 534, XP008070649 *
KRAETZSCHMAR J. ET AL.: "The human cysteine-rich secretory protein (CRISP) family, primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3", EUR. J. BIOCHEM., vol. 236, 1996, pages 827 - 836, XP000997999 *

Also Published As

Publication number Publication date
EP1572922A2 (en) 2005-09-14
JP2006501813A (en) 2006-01-19
WO2003076578A2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
WO2003031572A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2003066072A3 (en) Cell therapy using immunoregulatory t-cells
WO2004013310A3 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
ATE209684T1 (en) DNA SEQUENCES FOR MATRIX METAL PROTEASES, THEIR PREPARATION AND USE
WO2003076578A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003029429A3 (en) Traversal of nucleic acid molecules through a fluid space and expression in repair cells
WO2002040672A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2004050907A3 (en) Method for determing predisposition to manifestation of immune system related diseases
WO2004018633A3 (en) Abca13 nucleic acids and proteins, and uses thereof
HRP20020093A2 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO1999033979A3 (en) Bone marrow secreted proteins and polynucleotides
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
WO2003068921A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1277843A3 (en) Novel human genes and gene expression products related to colon cancer
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
EP2075346A3 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
WO2005014804A3 (en) Ubiquitin-specific protease
WO2001049879A3 (en) Methods for comparing gene expression levels or patterns in normal or tumor cells
EP1494031A3 (en) Novel human genes and gene expression products
CY1110911T1 (en) Human TSC403 gene
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003228284

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2478032

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003574785

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003726032

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003726032

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)